IDRA News and Press, Idera Pharmaceuticals Inc. From 03/08/21

Gainers: Second Sight Medical Products (EYES) +92%, OpGen (OPGN) +79%, Anchiano Therapeutics (ANCN) +64%, Jaguar Health (JAGX) +29%, Idera Pharmaceuticals (IDRA) +22%.Losers: Soleno Therapeutics (SLNO) -44%, AnaptysBio (ANAB) -34%, T...

Idera Pharmaceuticals (IDRA): Q4 GAAP EPS of -$2.11 misses by $1.88.Cash, cash equivalents, and short-term investments of $37.7M.Press Release For further details see: Idera Pharmaceuticals EPS misses by $1.88

EXTON, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the fourth quarter and year ended December 31, 2020. “Tilsotolimod is the most...

Mid-cap Idera Pharmaceutical ([[IDRA]] +1.5%) provides a preview for its cash runway and illustrates that if it announces additional capital raise of up to $20M after Phase 3 tilsotolimod data, it would be sufficient to run through Q1 2022 and further capital raise in mid-2021 of up $15M...

EXTON, Pa., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will provide a company outlook for 2021 at upcoming conferences. “2021 represents a pivotal inflection point for Idera, one in which we anticipate that data soon to ...

Idera Pharmaceuticals (IDRA) closed a second tranche under its Apr. 7, 2020, securities purchase agreement leading to total proceeds of up to $20.7M in common stock and warrant investment by funds affiliated with an institutional investor.Post the purchase agreement, Idera sold 2.75M shares u...

EXTON, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the closing of a second tranche under its April 7, 2020, securities purchase agreement (the “Purchase Agreement”), resulting in aggregate proceeds of up to $20.7 million in...

Gainers: Titan Pharmaceuticals (TTNP) +31%, Idera Pharmaceuticals (IDRA) +27%, Mesoblast (MESO) +20%, 22nd Century Group (XXII) +14%, Genfit (GNFT) +13%.Losers: AVROBIO (AVRO) -14%, Stealth BioTherapeutics (MITO) -14%, Kazia Therapeu...

Idera Pharmaceuticals (IDRA) appoints Daniel Soland as Senior VP and chief operating officer, effective Jan. 4, 2021.Soland has been engaged as a consultant to Idera for nearly three years. Most recently, he served as CEO at uniQure N.V. and prior to that, Senior VP & COO o...

– COO Role is Key to Preparedness for NDA Filing and Commercial Launch – – Clayton Fletcher , Head of Business Development & Strategic Planning , to Retire – EXTON, Pa., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Idera...